An orally bioavailable immunomodulator; induces expression of genes related to antigen presentation and inflammatory pathways in human PBMCs in vitro (0.1 μM); decreases the severity of symptoms by 91.4% and the number of relapses in mouse models of aEAE and crEAE, respectively (5 mg/kg per day); decreases T cell and macrophage density and demyelination in the spinal cord of EAE mice compared to non-treated controls (5 mg/kg per day); decreases inflammatory lesions and demyelination in the sciatic nerve in a rat EAN model (12.5 and 25 mg/kg per day); activates gene expression in the AhR pathway in splenocytes from EAE mice with no effect in AhR knockout mice (25 mg/kg per day)